CONDENSED CONSOLIDATED STATEMENTS OF SHAREHOLDERS' EQUITY (Unaudited) - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-In Capital	Accumulated Other Comprehensive Income (Loss)	Retained Earnings (Accumulated Deficit)
Beginning balance (in shares) at Jun. 30, 2024		2,279,948
Beginning balance at Jun. 30, 2024	$ 56,787	$ 114	$ 69,660	$ 8,584	$ (21,571)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	6,792				6,792
Foreign currency translation	(452)			(452)
Stock-based compensation	665		665
Net restricted stock activity (in shares)		15,481
Net restricted stock activity	(74)	$ 1	(75)
Common stock issued in connection with Alline acquisition (Note 13) (in shares)		140,550
Common stock issued in connection with Alline acquisition (Note 13)	3,000	$ 7	2,993
Ending balance (in shares) at Dec. 31, 2024		2,435,979
Ending balance at Dec. 31, 2024	66,718	$ 122	73,243	8,132	(14,779)
Beginning balance (in shares) at Sep. 30, 2024		2,282,395
Beginning balance at Sep. 30, 2024	56,398	$ 114	69,972	8,736	(22,424)
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	7,645				7,645
Foreign currency translation	(604)			(604)
Stock-based compensation	330		330
Net restricted stock activity (in shares)		13,034
Net restricted stock activity	(51)	$ 1	(52)
Common stock issued in connection with Alline acquisition (Note 13) (in shares)		140,550
Common stock issued in connection with Alline acquisition (Note 13)	3,000	$ 7	2,993
Ending balance (in shares) at Dec. 31, 2024		2,435,979
Ending balance at Dec. 31, 2024	$ 66,718	$ 122	73,243	8,132	(14,779)
Beginning balance (in shares) at Jun. 30, 2025	2,435,981	2,435,981
Beginning balance at Jun. 30, 2025	$ 185,616	$ 122	75,243	8,286	101,965
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	1,812				1,812
Foreign currency translation	(71)			(71)
Exercise of stock options (in shares)		24,564
Exercise of stock options	607	$ 1	606
Stock-based compensation	604		604
Net restricted stock activity (in shares)		25,666
Net restricted stock activity	(159)	$ 1	(160)
Common stock issued in connection with warrant exercise (in shares)		12,567
Common stock issued in connection with warrant exercise	$ 299	$ 1	298
Ending balance (in shares) at Dec. 31, 2025	2,498,778	2,498,778
Ending balance at Dec. 31, 2025	$ 188,708	$ 125	76,591	8,215	103,777
Beginning balance (in shares) at Sep. 30, 2025		2,461,270
Beginning balance at Sep. 30, 2025	187,551	$ 123	76,110	7,997	103,321
Increase (Decrease) in Stockholders' Equity [Roll Forward]
Net income	456				456
Foreign currency translation	218			218
Exercise of stock options (in shares)		13,564
Exercise of stock options	316	$ 1	315
Stock-based compensation	307		307
Net restricted stock activity (in shares)		23,944
Net restricted stock activity	$ (140)	$ 1	(141)
Ending balance (in shares) at Dec. 31, 2025	2,498,778	2,498,778
Ending balance at Dec. 31, 2025	$ 188,708	$ 125	$ 76,591	$ 8,215	$ 103,777